XOMAP XOMA Royalty Corp
Price Chart
Executive Summary
XOMA Royalty filed its preliminary proxy statement/prospectus on Form S-4 with the SEC in connection with the proposed acquisition by Ligand Pharmaceuticals. The filing confirms the all-cash deal at $39.00 per share plus one contingent value right (CVR) tied to the Janssen Litigation, with a special stockholder meeting to vote on the merger and holding company reorganization. No changes to deal terms were disclosed; this filing advances the deal toward the expected Q3 2026 close.
Key Financial Metrics
Actionable Insight
The filing confirms deal progression with no adverse changes. The key catalyst is the stockholder vote, which is virtually assured given BVF's 43.3% support. Monitor for HSR clearance and any potential competing bids before the vote. The CVR component is speculative and may take years to resolve.
Key Facts
- Ligand to acquire XOMA Royalty for $39.00 per share in cash plus one CVR per share tied to the Janssen Litigation
- Deal valued at approximately $739 million for the cash portion
- Special stockholder meeting to be held to vote on merger and holding company reorganization
- BVF Partners, holding ~43.3% of XOMA common stock, has agreed to vote in favor via Support Agreements
- Perpetual Preferred Stock (Series A and B) to be redeemed prior to closing
- Closing expected in Q3 2026, subject to stockholder and HSR approvals
- Termination fee of $40.0 million payable by XOMA under certain circumstances
Financial Impact
$39.00 per share cash consideration plus CVR; total cash consideration ~$739M based on ~18.9M fully diluted shares
Risk Factors
- Stockholder approval still required, though BVF's 43.3% support makes failure unlikely
- HSR waiting period must expire or be terminated
- Janssen Litigation may yield no recovery, making CVRs worthless
- Litigation challenging the merger could delay or prevent closing
- If deal fails, XOMA must pay $40M termination fee and faces operational uncertainty
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 425 Filing (Primary) | 0001193125-26-238267 |
| Document: 0001193125-26-238267-index-headers.html | 0001193125-26-238267 |
| Document: 0001193125-26-238267-index.html | 0001193125-26-238267 |
| Document: 0001193125-26-238267.txt | 0001193125-26-238267 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 10, 2026
2d ago
|
DEFM14A
| $25.51 awaiting T+5 | awaiting T+5 | — | $25.47 (−0.18%) |
|
May 26, 2026
18d ago
|
425
| $25.36 $25.38 | ▲ +0.09% | ▼ −1.00% | $25.47 (+0.41%) |
|
May 18, 2026
26d ago
|
DEFA14A
| $25.38 $25.36 | ▼ −0.07% | ▼ −1.69% | $25.47 (+0.33%) |
|
Apr 27, 2026
6w ago
|
DEFA14A
| $25.25 $25.24 | ▼ −0.04% | ▼ −0.44% | $25.47 (+0.85%) |
|
Apr 27, 2026
6w ago
|
8-K
| $25.25 $25.24 | ▼ −0.04% | ▼ −0.44% | $25.47 (+0.85%) |
|
Mar 30, 2026
10w ago
|
DEFA14A
| $25.74 $26.48 | ▲ +2.87% | ▼ −1.08% | $25.47 (−1.07%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access